<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MEGACE ES - megestrol acetate  suspension </strong><br>Stat Rx USA<br></p></div>
<h1>MEGACE ES (megestrol acetate oral suspension) suspension </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<a href="#section-"></a>DESCRIPTION<p class="First"><a href="#section-"></a>Megace <span class="Sup">®</span> ES (megestrol acetate) oral suspension contains megestrol 
acetate, a synthetic derivative of the naturally occurring steroid hormone, 
progesterone. Megestrol acetate is a white, crystalline solid chemically 
designated as 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate. Solubility 
at 37° C in water is 2 mcg per mL, solubility in plasma is 24 mcg per mL. Its 
molecular weight is 384.52.</p>
<p><a href="#section-"></a>The chemical formula is 
C<span class="Sub">24</span>H<span class="Sub">32</span>O<span class="Sub">4</span> 
and the structural formula is represented as follows:<br></p>
<br><p>                                                                                         <img alt="Structure Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=33bc102c-31a3-4fd9-9702-c1193d7699a3&amp;name=MegaceES_struct.jpg">                                                                   </p>                                                                                                                                                                                                <p><a href="#section-"></a>Megace <span class="Sup">®</span> ES (megestrol acetate) is a concentrated formula supplied as 
an oral suspension containing 125 mg of megestrol acetate per mL.</p>
<p><a href="#section-"></a>Megace <span class="Sup">®</span> ES (megestrol acetate) oral suspension contains the following 
inactive ingredients: alcohol (max 0.06% v/v from flavor), artificial lime 
flavor, citric acid monohydrate, docusate sodium, hydroxypropyl methylcellulose 
(hypromellose), natural and artificial lemon flavor, purified water, sodium 
benzoate, sodium citrate dihydrate, and sucrose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<a href="#section-"></a><span class="Bold">CLINICAL PHARMACOLOGY</span><p class="First"><a href="#section-"></a>There are several 
analytical methods used to estimate megestrol acetate plasma concentrations, 
including gas chromatography-<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> fragmentography (GC-MF), high pressure liquid 
chromatography (HPLC) and radioimmunoassay (RIA). The GC-MF and HPLC methods are 
specific for megestrol acetate and yield equivalent concentrations. The RIA 
method reacts to megestrol acetate metabolites and is, therefore, non-specific 
and indicates higher concentrations than the GC-MF and HPLC methods. Plasma 
concentrations are dependent, not only on the method used, but also on 
intestinal and hepatic inactivation of the drug, which may be affected by 
factors such as intestinal tract motility, intestinal bacteria, antibiotics 
administered, body weight, diet and liver function.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Mechanism of Action<p><a href="#section-"></a>Several investigators 
have reported on the appetite enhancing property of megestrol acetate and its 
possible use in <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>. The precise mechanism by which megestrol acetate 
produces effects in <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span> is unknown at the present time.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Pharmacokinetic Properties:<p><a href="#section-"></a>Plasma concentrations of 
megestrol acetate after administration of 625 mg (125 mg/mL) of Megace® ES oral 
suspension are equivalent under fed conditions to 800 mg (40 mg/mL) of megestrol 
acetate oral suspension (see figure below).</p>                                                                                                    <div class="Figure"><img alt="Graph Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=33bc102c-31a3-4fd9-9702-c1193d7699a3&amp;name=MegaceES_graph.jpg"></div>                                                                                                 <br>                                                                  <span class="Bold">                                                                           </span><p><a href="#section-"></a>In order to characterize 
the dose proportionality of Megace® ES, pharmacokinetic studies across a range 
of doses were conducted when administered under fasting and fed conditions. 
Pharmacokinetics of megestrol was linear in the dosing range between 150 mg and 
675 mg after Megace® ES administration regardless of meal condition. The Cmax 
and AUC under a high fat meal were increased by 48% and 36%, respectively, 
compared to those under the fasting after 625 mg Megace® ES administration 
(Table 1). However, a high fat meal significantly increased AUC and Cmax of 
megestrol to 2-fold and 7-fold, respectively, compared to those under fasting 
condition after administration of 800 mg in the original formulation. There was 
no difference in safety following administration in the fed state, therefore 
Megace® ES could be taken without regard to meals.</p>
<a href="#section-"></a><a name="ia54958ee-5a81-4a35-8c15-ec2e7703afbb"></a><table border="1">
<col width="56">
<col width="32">
<col width="32">
<col width="32">
<col width="32">
<col width="32">
<col width="36">
<col width="32">
<col width="36">
<col width="28">
<col width="36">
<col width="36">
<col width="36">
<col width="36">
<col width="36">
<col width="32">
<col width="36">
<tbody class="Headless"><tr class="First Last"><td><p class="First"><a href="#section-"></a>*megestrol acetate oral 
suspension</p></td></tr></tbody>
<tbody class="Headless">
<tr class="First"><td>Table 1 - Pharmacokinetic 
Studies Conducted with Megace® ES </td></tr>
<tr>
<td>Amount Dosed </td>
<td>150 mg </td>
<td>250 mg </td>
<td>375 mg </td>
<td>450 mg </td>
<td>575 mg </td>
<td>625 mg </td>
<td>675 mg </td>
<td>800 mg* </td>
</tr>
<tr>
<td>Dose </td>
<td>5 mL </td>
<td>5 mL </td>
<td>5 mL </td>
<td>5 mL </td>
<td>5 mL </td>
<td>5 mL </td>
<td>5 mL </td>
<td>20 mL </td>
</tr>
<tr>
<td>  </td>
<td>Fast </td>
<td>Fed </td>
<td>Fast </td>
<td>Fed </td>
<td>Fast </td>
<td>Fed </td>
<td>Fast </td>
<td>Fed </td>
<td>Fast </td>
<td>Fed </td>
<td>Fast </td>
<td>Fed </td>
<td>Fast </td>
<td>Fed </td>
<td>Fast </td>
<td>Fed </td>
</tr>
<tr>
<td>C<span class="Sub">max</span> (ng/mL) </td>
<td>412 </td>
<td>379 </td>
<td>647 </td>
<td>588 </td>
<td>810 </td>
<td>958 </td>
<td>955 </td>
<td>1079 </td>
<td>- </td>
<td>1421 </td>
<td>1133 </td>
<td>1618 </td>
<td>1044 </td>
<td>1616 </td>
<td>187 </td>
<td>1364 </td>
</tr>
<tr>
<td>AUC0-∞ (ng∙h/mL) </td>
<td>3058 </td>
<td>3889 </td>
<td>5194 </td>
<td>6328 </td>
<td>7238 </td>
<td>12193 </td>
<td>9483 </td>
<td>11800 </td>
<td>- </td>
<td>14743 </td>
<td>12095 </td>
<td>16268 </td>
<td>11879 </td>
<td>17029 </td>
<td>8942 </td>
<td>18625 </td>
</tr>
<tr class="Last">
<td>Tmax (h) </td>
<td>1.74 </td>
<td>3.80 </td>
<td>1.58 </td>
<td>3.38 </td>
<td>1.56 </td>
<td>3.42 </td>
<td>1.74 </td>
<td>3.16 </td>
<td>- </td>
<td>3.75 </td>
<td>1.72 </td>
<td>2.91 </td>
<td>1.96 </td>
<td>2.76 </td>
<td>5.89 </td>
<td>3.85 </td>
</tr>
</tbody>
</table>
<p><a href="#section-"></a>Plasma steady state 
pharmacokinetics of megestrol acetate were evaluated in 10 adult, cachectic male 
patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS) and an involuntary 
<span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> greater than 10% of baseline. Patients received single oral doses of 
800 mg/day of megestrol acetate oral suspension for 21 days. Plasma 
concentration data obtained on day 21 were evaluated for up to 48 hours past the 
last dose.</p>
<p><a href="#section-"></a>Mean (±1SD) peak plasma 
concentration (Cmax) of megestrol acetate was 753 (±539) ng/mL. Mean area under 
the concentration time-curve (AUC) was 10476 (±7788) ng x hr/mL. Median Tmax 
value was five hours. Seven of 10 patients gained weight in three weeks.</p>
<p><a href="#section-"></a>Additionally, 24 adult, 
asymptomatic HIV seropositive male subjects were dosed once daily with 750 mg of 
megestrol acetate oral suspension. The treatment was administered for 14 days. 
Mean Cmax and AUC values were 490 (±238) ng/mL and 6779 (±3048) hr x ng/mL, 
respectively. The median Tmax value was three hours. The mean Cmax value was 202 
(±101) ng/mL. The mean % of fluctuation value was 107 (±40).</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Metabolism<p><a href="#section-"></a>Megestrol acetate 
metabolites which were identified in urine constituted 5% to 8% of the dose 
administered. Respiratory excretion as labeled <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and fat storage 
may have accounted for at least part of the radioactivity not found in urine and 
feces.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Elimination<p><a href="#section-"></a>The major route of drug 
elimination in humans is urine. When radiolabeled megestrol acetate was 
administered to humans in doses of 4 to 90 mg, the urinary excretion within 10 
days ranged from 56.5% to 78.4% (mean 66.4%) and fecal excretion ranged from 
7.7% to 30.3% (mean 19.8%). The total recovered radioactivity varied between 
83.1% and 94.7% (mean 86.2%).</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Special Populations<p><a href="#section-"></a>The pharmacokinetics of 
megestrol acetate has not been studied in any special populations.</p>
<a href="#section-"></a><span class="Bold">ANIMAL PHARMACOLOGY AND/OR TOXICOLOGY</span><p><a href="#section-"></a>Long-term treatment with 
Megace <span class="Sup">®</span> ES (megestrol acetate) may increase the risk of 
<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infections</span>. A trend toward increased frequency of respiratory 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, decreased lymphocyte counts and increased neutrophil counts was 
observed in a two-year chronic toxicity/carcinogenicity study of megestrol 
acetate conducted in rats.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><span class="Bold">DESCRIPTION OF CLINICAL STUDIES</span><p><a href="#section-"></a>Megestrol acetate oral 
suspension at a dose of 800 mg/20 mL is equivalent to 625 mg/5 mL of Megace 
<span class="Sup">®</span> ES. The clinical efficacy of megestrol acetate oral 
suspension was assessed in two clinical trials. One was a multicenter, 
randomized, double-blind, placebo-controlled study comparing megestrol acetate 
(MA) at doses of 100 mg, 400 mg, and 800 mg per day versus placebo in AIDS 
patients with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>/<span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span> and significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. Of the 270 patients 
entered on study, 195 met all inclusion/exclusion criteria, had at least two 
additional post baseline weight measurements over a 12 week period or had one 
post baseline weight measurement but dropped out for therapeutic failure. The 
percent of patients gaining five or more pounds at maximum <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in 12 
study weeks was statistically significantly greater for the 800 mg (64%) and 400 
mg (57%) MA-treated groups than for the placebo group (24%). Mean weight 
increased from baseline to last evaluation in 12 study weeks in the 800 mg 
MA-treated group by 7.8 pounds, the 400 mg MA group by 4.2 pounds, the 100 mg MA 
group by 1.9 pounds and decreased in the placebo group by 1.6 pounds. Mean 
weight changes at 4, 8 and 12 weeks for patients evaluable for efficacy in the 
two clinical trials are shown graphically. Changes in body composition during 
the 12 study weeks as measured by bioelectrical impedance analysis showed 
increases in non-water body weight in the MA-treated groups (see clinical 
studies table). In addition, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> developed or worsened in only 3 patients.</p>
<p><a href="#section-"></a>Greater percentages of 
MA-treated patients in the 800 mg group (89%), the 400 mg group (68%) and the 
100 mg group (72%), than in the placebo group (50%), showed an improvement in 
appetite at last evaluation during the 12 study weeks. A statistically 
significant difference was observed between the 800 mg MA-treated group and the 
placebo group in the change in caloric intake from baseline to time of maximum 
weight change. Patients were asked to assess weight change, appetite, 
appearance, and overall perception of well-being in a 9 question survey. At 
maximum weight change only the 800 mg MA-treated group gave responses that were 
statistically significantly more favorable to all questions when compared to the 
placebo-treated group. A dose response was noted in the survey with positive 
responses correlating with higher dose for all questions.</p>
<p><a href="#section-"></a>The second trial was a 
multicenter, randomized, double-blind, placebo-controlled study comparing 
megestrol acetate 800 mg/day versus placebo in AIDS patients with 
<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>/<span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span> and significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. Of the 100 patients entered on 
study, 65 met all inclusion/exclusion criteria, had at least two additional post 
baseline weight measurements over a 12 week period or had one post baseline 
weight measurement but dropped out for therapeutic failure. Patients in the 800 
mg MA-treated group had a statistically significantly larger increase in mean 
maximum weight change than patients in the placebo group. From baseline to study 
week 12, mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span> by 11.2 pounds in the MA-treated group and 
decreased 2.1 pounds in the placebo group. Changes in body composition as 
measured by bioelectrical impedance analysis showed increases in non-water 
weight in the MA-treated group (see clinical studies table). No <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was 
reported in the MA-treated group. A greater percentage of MA-treated patients 
(67%) than placebo-treated patients (38%) showed an improvement in appetite at 
last evaluation during the 12 study weeks; this difference was statistically 
significant. There were no statistically significant differences between 
treatment groups in mean caloric change or in daily caloric intake at time to 
maximum weight change. In the same 9 question survey referenced in the first 
trial, patients’ assessments of weight change, appetite, appearance, and overall 
perception of well-being showed increases in mean scores in MA-treated patients 
as compared to the placebo group.</p>
<p><a href="#section-"></a>In both trials, patients 
tolerated the drug well and no statistically significant differences were seen 
between the treatment groups with regard to laboratory abnormalities, new 
<span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>, lymphocyte counts, T4 counts, T8 counts, or skin 
reactivity tests (see <span class="Bold">ADVERSE</span><span class="Bold">REACTIONS 
</span>section).</p>
<a href="#section-"></a><a name="ifb1c0199-c2fb-4b13-86ca-b5c6fc34d4fa"></a><table border="1">
<col width="316">
<col width="60">
<col width="56">
<col width="36">
<col width="44">
<col width="16">
<col width="44">
<col width="56">
<tbody class="Headless">
<tr class="First"><td>Megestrol Acetate Oral 
Suspension Clinical Efficacy Trials </td></tr>
<tr>
<td>  </td>
<td>Trial 1 </td>
<td>Trial 2 </td>
</tr>
<tr>
<td>  </td>
<td>Study Accrual Dates </td>
<td>Study Accrual Dates </td>
</tr>
<tr>
<td>  </td>
<td>11/88 to 12/90 </td>
<td>5/89 to 4/91 </td>
</tr>
<tr>
<td>Megestrol Acetate, mg/day </td>
<td>0 </td>
<td>100 </td>
<td>400 </td>
<td>800 </td>
<td>  </td>
<td>0 </td>
<td>800 </td>
</tr>
<tr>
<td>Entered Patients </td>
<td>38 </td>
<td>82 </td>
<td>75 </td>
<td>75 </td>
<td>  </td>
<td>48 </td>
<td>52 </td>
</tr>
<tr>
<td>Evaluable Patients </td>
<td>28 </td>
<td>61 </td>
<td>53 </td>
<td>53 </td>
<td>  </td>
<td>29 </td>
<td>36 </td>
</tr>
<tr>
<td>Mean Change in Weight (lb.) </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
</tr>
<tr>
<td>Baseline to 12 Weeks </td>
<td>0.0 </td>
<td>2.9 </td>
<td>9.3 </td>
<td>10.7 </td>
<td>  </td>
<td>-2.1 </td>
<td>11.2 </td>
</tr>
<tr>
<td>% Patients ≥ 5 Pound Gain </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
</tr>
<tr>
<td>At Last Evaluation in 12 weeks </td>
<td>21 </td>
<td>44 </td>
<td>57 </td>
<td>64 </td>
<td>  </td>
<td>28 </td>
<td>47 </td>
</tr>
<tr>
<td>Mean Changes in Body Composition: </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
</tr>
<tr>
<td>Fat Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> (lb.) </td>
<td>0.0 </td>
<td>2.2 </td>
<td>2.9 </td>
<td>5.5 </td>
<td>  </td>
<td>1.5 </td>
<td>5.7 </td>
</tr>
<tr>
<td>Lean Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> (lb.) </td>
<td>-1.7 </td>
<td>-0.3 </td>
<td>1.5 </td>
<td>2.5 </td>
<td>  </td>
<td>-1.6 </td>
<td>-0.6 </td>
</tr>
<tr>
<td>Water (liters) </td>
<td>-1.3 </td>
<td>-0.3 </td>
<td>0.0 </td>
<td>0.0 </td>
<td>  </td>
<td>-0.1 </td>
<td>-0.1 </td>
</tr>
<tr>
<td>% Patients With Improved Appetite: </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
</tr>
<tr>
<td>At Time of Maximum Weight Change </td>
<td>50 </td>
<td>72 </td>
<td>72 </td>
<td>93 </td>
<td>  </td>
<td>48 </td>
<td>69 </td>
</tr>
<tr>
<td>At Last Evaluation in 12 Weeks </td>
<td>50 </td>
<td>72 </td>
<td>68 </td>
<td>89 </td>
<td>  </td>
<td>38 </td>
<td>67 </td>
</tr>
<tr>
<td>Mean Change in Daily Caloric Intake: </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>  </td>
</tr>
<tr>
<td>Baseline to Time of Maximum Weight Change</td>
<td>-107 </td>
<td>326 </td>
<td>308 </td>
<td>646 </td>
<td>  </td>
<td>30 </td>
<td>464 </td>
</tr>
<tr class="Last"><td>*Based on bioelectrical impedance analysis 
determinations at last evaluation in 12 weeks </td></tr>
</tbody>
</table>
<p><a href="#section-"></a>Presented below are the 
results of mean weight changes for patients evaluable for efficacy in trials 1 
and 2.</p>
<br><p>                                                                          <img alt="Trial1 Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=33bc102c-31a3-4fd9-9702-c1193d7699a3&amp;name=MegaceES_trial1.jpg">                <img alt="Trial2 Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=33bc102c-31a3-4fd9-9702-c1193d7699a3&amp;name=MegaceES_trial2.jpg"></p>
<p><br></p>
<br><p>                                                                                                </p>
<p><br></p>
<br><p>                                                                                        </p>
<p><br></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<a href="#section-"></a><span class="Bold">INDICATIONS AND USAGE</span><p class="First"><a href="#section-"></a>Megace <span class="Sup">®</span> ES (megestrol acetate) oral suspension is indicated for the 
treatment of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>, or an unexplained, significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> in 
patients with a diagnosis of <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS). </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<a href="#section-"></a><span class="Bold">CONTRAINDICATIONS</span><p class="First"><a href="#section-"></a>History of 
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to megestrol acetate or any component of the formulation. Known 
or suspected pregnancy.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<a href="http://"></a><span class="Bold">WARNINGS</span><p class="First"><a href="http://"></a>Megestrol acetate may 
cause fetal harm when administered to a pregnant woman. For animal data on fetal 
effects, (see <span class="Bold">PRECAUTIONS:</span><span class="Bold">Impairment of 
Fertility</span> section). There are no adequate and well-controlled studies in 
pregnant women. If this drug is used during pregnancy, or if the patient becomes 
pregnant while taking (receiving) this drug, the patient should be apprised of 
the potential hazard to the fetus. Women of childbearing potential should be 
advised to avoid becoming pregnant.</p>
<p><a href="http://"></a>Megestrol acetate is not 
intended for <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use to avoid <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</p>
<p><a href="http://"></a>(See also <span class="Bold">PRECAUTIONS: Carcinogenesis, Mutagenesis, and Impairment of 
Fertility</span> section).</p>
<p><a href="http://"></a>The glucocorticoid 
activity of megestrol acetate oral suspension has not been fully evaluated. 
Clinical cases of new onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, exacerbation of pre-existing 
<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and overt Cushing’s Syndrome have been reported in 
association with the chronic use of megestrol acetate. In addition, clinical 
cases of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> have been observed in patients receiving or being 
withdrawn from chronic megestrol acetate therapy in the stressed and 
non-stressed state. Furthermore, adrenocorticotropin (ACTH) stimulation testing 
has revealed the frequent occurrence of asymptomatic pituitary-adrenal 
suppression in patients treated with chronic megestrol acetate therapy. 
Therefore, the possibility of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> should be considered in any 
patient receiving or being withdrawn from chronic Megace <span class="Sup">®</span> ES therapy who presents with symptoms and/or signs suggestive 
of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span> (e.g., <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>) 
in either the stressed or non-stressed state. Laboratory evaluation for adrenal 
insufficiency and consideration of replacement or stress doses of a rapidly 
acting glucocorticoid are strongly recommended in such patients. Failure to 
recognize inhibition of the hypothalamic-pituitary-adrenal axis may result in 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Finally, in patients who are receiving or being withdrawn from chronic 
Megace<span class="Sup">®</span> ES therapy, consideration should be given to the 
use of empiric therapy with stress doses of a rapidly acting glucocorticoid 
during stress or serious intercurrent illness (e.g., surgery, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>).</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Bold"> PRECAUTIONS</span><br><span class="Bold">GENERAL</span><br><p><a href="http://"></a>Therapy with Megace 
<span class="Sup">®</span> ES (megestrol acetate) oral suspension for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> 
should only be instituted after treatable causes of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> are sought and 
addressed. These treatable causes include possible malignancies, systemic 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> affecting absorption, endocrine disease 
and renal or psychiatric diseases.</p>
<p><a href="http://"></a>Effects on HIV viral 
replication have not been determined.</p>
<p><a href="http://"></a>Use with caution in 
patients with a history of thromboembolic disease.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Use in Diabetics<p><a href="http://"></a>Exacerbation of 
pre-existing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with increased insulin requirements have been reported in 
association with the use of megestrol acetate.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6"></a><p></p>
<a href="#section-"></a><span class="Bold">Information for Patients</span><p class="First"><a href="#section-"></a>Patients using Megace 
<span class="Sup">®</span> ES (megestrol acetate) should receive the following 
instructions:</p>
<ol>
<li>This medication is to be used as directed by the physician. 
</li>
<li>Megace® ES (625 mg/5 mL) does not contain the same amount of megestrol 
acetate as Megace® oral suspension or any of the other megestrol acetate oral 
suspensions. Megace® ES contains 625 mg of megestrol acetate per 5 mL whereas 
Megace® oral suspension and other megestrol acetate oral suspensions contain 800 
mg per 20 mL. 
</li>
<li><span class="Bold">The prescriber should inform the patient about the product 
differences to avoid overdosing or underdosing of megestrol acetate. The 
recommended adult dosage of Megace® ES is one teaspoon (5 mL) once a day. Please 
see table in DOSAGE AND ADMINISTRATION section.</span></li>
<li>Report any adverse reaction experiences while taking this medication. 
</li>
<li>Use contraception while taking this medication if you are a woman capable of 
becoming pregnant. 
</li>
<li>Notify your physician if you become pregnant while taking this medication. 
</li>
</ol>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Drug Interactions<p><a href="#section-"></a>Pharmacokinetic studies 
show that there are no significant alterations in pharmacokinetic parameters of 
zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is 
administered with these drugs. A pharmacokinetic study demonstrated that 
coadministration of megestrol acetate and indinavir results in a significant 
decrease in the pharmacokinetic parameters (~36% for C <span class="Sub">max</span> and ~28% for AUC) of indinavir. Administration of a higher 
dose of indinavir should be considered when coadministering with megestrol 
acetate. The effects of indinavir, zidovudine or rifabutin on the 
pharmacokinetics of megestrol acetate were not studied.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Carcinogenesis and Mutagenesis and Impairment of 
Fertility<p><a href="#section-"></a>Data on carcinogenesis 
were obtained from studies conducted in dogs, monkeys and rats treated with 
megestrol acetate at doses 53.2, 26.6 and 1.3 times lower than the proposed dose 
(13.3 mg/kg/day) for humans. No males were used in the dog and monkey studies. 
In female beagles, megestrol acetate (0.01, 0.1 or 0.25 mg/kg/day) administered 
for up to 7 years induced both benign and <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span> of the breast. In 
female monkeys, no tumors were found following 10 years of treatment with 0.01, 
0.1 or 0.5 mg/kg/day megestrol acetate. Pituitary tumors were observed in female 
rats treated with 3.9 or 10 mg/kg/day of megestrol acetate for 2 years. The 
relationship of these tumors in rats and dogs to humans is unknown but should be 
considered in assessing the risk-to-benefit ratio when prescribing Megace <span class="Sup">®</span> ES (megestrol acetate) oral suspension and in surveillance of 
patients on therapy. (See <span class="Bold">WARNINGS</span> section).</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Mutagenesis<p><a href="#section-"></a>No mutagenesis data are 
currently available.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Impairment of Fertility<p><a href="#section-"></a>Perinatal/postnatal 
(segment III) toxicity studies were performed in rats at doses (0.05 to 12.5 
mg/kg) <span class="Italics">less</span> than that indicated for humans (13.3 
mg/kg); in these low dose studies, the reproductive capability of male offspring 
of megestrol acetate-treated females was impaired. Similar results were obtained 
in dogs. Pregnant rats treated with megestrol acetate showed a reduction in 
fetal weight and number of live births, and <span class="product-label-link" type="condition" conceptid="4140373" conceptname="Feminized male">feminization</span> of male fetuses. No 
toxicity data are currently available on male reproduction 
(spermatogenesis).</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Pregnancy<p><a href="#section-"></a><span class="Bold">Pregnancy Category X</span>. (See <span class="Bold">WARNINGS</span> 
and <span class="Bold">PRECAUTIONS: Impairment of Fertility</span> sections). No 
adequate animal teratology information is available at clinically relevant 
doses.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Nursing Mothers<p><a href="#section-"></a>Because of the potential 
for adverse effects on the newborn, nursing should be discontinued if Megace 
<span class="Sup">®</span> ES (megestrol acetate) oral suspension is 
required.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Use in HIV Infected Women<p><a href="#section-"></a>Although megestrol 
acetate has been used extensively in women for the treatment of endometrial and 
breast cancers, its use in HIV infected women has been limited.</p>
<p><a href="#section-"></a>All 10 women in the 
clinical trials reported breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Pediatric Use<p><a href="#section-"></a>Safety and effectiveness 
in pediatric patients have not been established.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Geriatric Use<p><a href="#section-"></a>Clinical studies of 
megestrol acetate oral suspension in the treatment of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>, or an 
unexplained, significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> in patients with AIDS did not include 
sufficient numbers of patients aged 65 years and older to determine whether they 
respond differently than younger patients. Other reported clinical experience 
has not identified differences in responses between elderly and younger 
patients. In general, dose selection for an elderly patient should be cautious, 
usually starting at the low end of the dosing range, reflecting the greater 
frequency of decreased hepatic, renal, or cardiac function, and of concomitant 
disease or other drug therapy.</p>
<p><a href="#section-"></a>Megestrol acetate is 
known to be substantially excreted by the kidney, and the risk of toxic 
reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. 
Because elderly patients are more likely to have decreased renal function, care 
should be taken in dose selection, and it may be useful to monitor renal 
function.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<a href="http://"></a><span class="Bold">ADVERSE REACTIONS</span><p class="First"><a href="http://"></a><span class="Bold">Clinical Adverse Events</span></p>
<p><a href="http://"></a>Adverse events which 
occurred in at least 5% of patients in any arm of the two clinical efficacy 
trials and the open trial are listed below by treatment group. All patients 
listed had at least one post baseline visit during the 12 study weeks. These 
adverse events should be considered by the physician when prescribing Megace 
<span class="Sup">®</span> ES (megestrol acetate) oral suspension.</p>
<a href="http://"></a><a name="ie61a7fdd-a452-4dda-8342-c370ac837946"></a><table border="1">
<col width="108">
<col width="64">
<col width="48">
<col width="48">
<col width="48">
<col width="64">
<col width="48">
<col width="84">
<col width="72">
<tbody class="Headless">
<tr class="First"><td>
<span class="Bold">ADVERSE 
EVENTS</span><span class="Bold">% of Patients Reporting</span>
</td></tr>
<tr>
<td><span class="Bold"> </span></td>
<td>  </td>
<td>  </td>
<td>Open </td>
</tr>
<tr>
<td><span class="Bold"> </span></td>
<td>Trial 1 (N=236) </td>
<td>Trial 2 (N=87) </td>
<td>Label Trial </td>
</tr>
<tr>
<td>Megestrol Acetate, </td>
<td>Placebo </td>
<td>  </td>
<td>  </td>
<td>  </td>
<td>Placebo </td>
<td>  </td>
<td>  </td>
</tr>
<tr>
<td>mg/day </td>
<td>0 </td>
<td>100 </td>
<td>400 </td>
<td>800 </td>
<td>0 </td>
<td>800 </td>
<td>1200 </td>
</tr>
<tr>
<td>No. of Patients </td>
<td>N=34 </td>
<td>N=68 </td>
<td>N=69 </td>
<td>N=65 </td>
<td>N=38 </td>
<td>N=49 </td>
<td>N=176 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td>15 </td>
<td>13 </td>
<td>8 </td>
<td>15 </td>
<td>8 </td>
<td>6 </td>
<td>10 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span> </td>
<td>3 </td>
<td>4 </td>
<td>6 </td>
<td>14 </td>
<td>0 </td>
<td>4 </td>
<td>7 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td>9 </td>
<td>9 </td>
<td>4 </td>
<td>12 </td>
<td>3 </td>
<td>2 </td>
<td>6 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> </td>
<td>9 </td>
<td>0 </td>
<td>1 </td>
<td>9 </td>
<td>3 </td>
<td>10 </td>
<td>6 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </td>
<td>0 </td>
<td>0 </td>
<td>0 </td>
<td>8 </td>
<td>0 </td>
<td>0 </td>
<td>4 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </td>
<td>3 </td>
<td>2 </td>
<td>3 </td>
<td>6 </td>
<td>8 </td>
<td>4 </td>
<td>5 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </td>
<td>0 </td>
<td>3 </td>
<td>4 </td>
<td>6 </td>
<td>0 </td>
<td>0 </td>
<td>1 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td>9 </td>
<td>4 </td>
<td>0 </td>
<td>5 </td>
<td>3 </td>
<td>4 </td>
<td>5 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </td>
<td>6 </td>
<td>3 </td>
<td>3 </td>
<td>5 </td>
<td>0 </td>
<td>0 </td>
<td>0 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </td>
<td>3 </td>
<td>6 </td>
<td>4 </td>
<td>5 </td>
<td>3 </td>
<td>2 </td>
<td>1 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido Decreased</span> </td>
<td>3 </td>
<td>4 </td>
<td>0 </td>
<td>5 </td>
<td>0 </td>
<td>2 </td>
<td>1 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </td>
<td>0 </td>
<td>0 </td>
<td>3 </td>
<td>3 </td>
<td>5 </td>
<td>4 </td>
<td>2 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> </td>
<td>3 </td>
<td>0 </td>
<td>6 </td>
<td>3 </td>
<td>0 </td>
<td>0 </td>
<td>3 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td>6 </td>
<td>10 </td>
<td>1 </td>
<td>3 </td>
<td>3 </td>
<td>0 </td>
<td>3 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </td>
<td>6 </td>
<td>0 </td>
<td>0 </td>
<td>2 </td>
<td>5 </td>
<td>6 </td>
<td>4 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td>9 </td>
<td>3 </td>
<td>0 </td>
<td>2 </td>
<td>3 </td>
<td>6 </td>
<td>4 </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> </td>
<td>6 </td>
<td>2 </td>
<td>0 </td>
<td>2 </td>
<td>3 </td>
<td>0 </td>
<td>1 </td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary Frequency</span> </td>
<td>0 </td>
<td>0 </td>
<td>1 </td>
<td>2 </td>
<td>5 </td>
<td>2 </td>
<td>1 </td>
</tr>
</tbody>
</table>
<p><a href="http://"></a>Adverse events which 
occurred in 1% to 3% of all patients enrolled in the two clinical efficacy 
trials with at least one follow-up visit during the first 12 weeks of the study 
are listed below by body system. Adverse events occurring less than 1% are not 
included. There were no significant differences between incidence of these 
events in patients treated with megestrol acetate and patients treated with 
placebo.</p>
<p><a href="http://"></a>Body as a Whole - 
<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> and <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span></p>
<p><a href="http://"></a>Cardiovascular System - 
<span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span></p>
<p><a href="http://"></a>Digestive System - 
<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span> and oral 
<span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span></p>
<p><a href="http://"></a>Hemic and Lymphatic 
System - <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span></p>
<p><a href="http://"></a>Metabolic and 
Nutritional - LDH increased, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span></p>
<p><a href="http://"></a>Nervous System - 
<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span> and 
<span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span></p>
<p><a href="http://"></a>Respiratory System - 
<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disorder</span></p>
<p><a href="http://"></a>Skin and Appendages - 
<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, herpes, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span></p>
<p><a href="http://"></a>Special Senses - 
<span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span></p>
<p><a href="http://"></a>Urogenital System - 
<span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> and 
<span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span></p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Postmarketing<p><a href="http://"></a>Postmarketing reports 
associated with megestrol acetate oral suspension include thromboembolic 
phenomena including <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, and pulmonary 
<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>; and <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> (see <span class="Bold">WARNINGS</span> and 
<span class="Bold">PRECAUTIONS</span> sections).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<a href="http://"></a><span class="Bold">OVERDOSAGE</span><p class="First"><a href="http://"></a>No serious unexpected 
side effects have resulted from studies involving megestrol acetate oral 
suspension administered in dosages as high as 1200 mg/day. Megestrol acetate has 
not been tested for dialyzability; however, due to its low solubility it is 
postulated that dialysis would not be an effective means of treating <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<a href="http://"></a><span class="Bold">DOSAGE AND ADMINISTRATION</span><p class="First"><a href="http://"></a>The recommended adult 
initial dosage of Megace <span class="Sup">®</span> ES (megestrol acetate) oral 
suspension is 625 mg/day (5 mL/day or one teaspoon daily). <span class="Bold">Please refer to the table below for correct dosing and 
administration</span>. Shake container well before using.</p>
<a href="http://"></a><a name="i8569ac3d-6ce8-40cc-86ef-c75992728236"></a><table border="1">
<col width="124">
<col width="232">
<col width="264">
<tbody class="Headless">
<tr class="First"><td><span class="Bold"><span class="Italics">PRODUCT DIFFERENCES</span></span></td></tr>
<tr>
<td>  </td>
<td>Megace<span class="Sup">®</span> ES Oral Suspension 
</td>
<td>Megace<span class="Sup">®</span> and other 
megestrol acetate oral suspensions </td>
</tr>
<tr>
<td>mg/mL </td>
<td>125 mg/mL </td>
<td>40 mg/mL </td>
</tr>
<tr>
<td>Recommended Daily Dose </td>
<td>625 mg </td>
<td>800 mg </td>
</tr>
<tr>
<td>Daily Volume Intake </td>
<td>5 mL (teaspoon) </td>
<td>20 mL (dosing cup) </td>
</tr>
<tr class="Last">
<td>Formulation </td>
<td>Concentrated formula </td>
<td>Regular formula </td>
</tr>
</tbody>
</table>
<p><a href="http://"></a>In clinical trials 
evaluating different dose schedules, daily doses of 400 and 800 mg/day of 
megestrol acetate oral suspension (800 mg/20 mL equivalent to 625 mg/5 mL of 
Megace <span class="Sup">®</span> ES formula) were found to be clinically 
effective.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<a href="http://"></a><span class="Bold">HOW SUPPLIED</span><p class="First"><a href="http://"></a>Megace <span class="Sup">®</span> ES (megestrol acetate) oral suspension is a concentrated 
formula available as a milky white, lemon-lime flavored oral suspension 
containing 125 mg of megestrol acetate per mL.</p>
<a href="http://"></a><a name="i11c94c41-042c-4679-86b5-b6755648a8a5"></a><table border="1">
<col width="156">
<col width="448">
<tbody class="Headless"><tr class="First Last">
<td>NDC 49884-949-69 </td>
<td>Bottles of 150 mL (5 fl. oz.) 
</td>
</tr></tbody>
</table>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Bold">STORAGE</span><p><a href="http://"></a>Store Megace <span class="Sup">®</span> ES (megestrol acetate) oral suspension between 15º to 25º C 
(59º to 77º F) and dispense in a tight container. Protect from heat.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Bold">SPECIAL HANDLING</span><p><a href="http://"></a><span class="Bold">Health 
Hazard Data</span></p>
<p><a href="http://"></a>There is no threshold 
limit value established by OSHA, NIOSH, or ACGIH.</p>
<p><a href="http://"></a>Exposure or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> at 
levels approaching recommended dosing levels could result in side effects 
described above (see <span class="Bold">WARNINGS</span> and <span class="Bold">ADVERSE REACTIONS</span> sections). Women at risk of pregnancy should 
avoid such exposure.</p>
<p><a href="http://"></a>Manufactured by:</p>
<p><a href="http://"></a>P<span class="Bold">AR 
PHARMACEUTICAL COMPANIES, INC.</span></p>
<p><a href="http://"></a>Spring Valley, New York 
10977</p>
<p><a href="http://"></a></p>
<a href="http://"></a><a name="i2955fdc5-fcc3-4a36-89a1-20b9fb4a5b98"></a><table>
<col width="312">
<col width="308">
<tbody class="Headless"><tr class="First Last">
<td>Revised: 05/08</td>
<td>OS939-51-1-03 </td>
</tr></tbody>
</table>
<p><a href="http://"></a>Megace <span class="Sup">®</span> is a registered trademark of Bristol-Myers Squibb Company 
licensed to Par Pharmaceutical, Inc.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<p class="First"><span class="Bold">MEGACE ES PACKAGE LABEL</span></p>
<br><p>                                                <img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=33bc102c-31a3-4fd9-9702-c1193d7699a3&amp;name=MegaceES_label.jpg"></p>
<p><br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MEGACE ES 		
					</strong><br><span class="contentTableReg">megestrol acetate  suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-254(NDC:49884-949)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MEGESTROL ACETATE </strong> (MEGESTROL) </td>
<td class="formItem">MEGESTROL ACETATE </td>
<td class="formItem">125 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-254-33</td>
<td class="formItem">150 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021778</td>
<td class="formItem">06/08/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Stat Rx USA
							(786036330)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>466ac927-6b60-4932-8260-dbd38aaedd6b</div>
<div>Set id: 33bc102c-31a3-4fd9-9702-c1193d7699a3</div>
<div>Version: 2</div>
<div>Effective Time: 20091027</div>
</div>
</div> <div class="DistributorName">Stat Rx USA</div></p>
</body></html>
